Say Goodbye to Frequent Injections: FDA Gives Thumbs Up to OCREVUS ZUNOVO for MS Patients!
Roche Announces FDA Approval of OCREVUS ZUNOVO™ for Multiple Sclerosis Treatment Basel, 16 September 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Breaking…